Puma Reports Q1 Revenue of $44.8M, Raises 2026 Revenue Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Reports Q1 revenue $44.8M vs $42M last year. "We are very pleased that the first quarter of 2026 marked another quarter of year-over-year demand increase resulting in our raising revenue guidance for 2026. According to our current forecasts, FY 2026 will mark our second consecutive year of NERLYNX demand increase year over year," said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. "We are also pleased with the interim data from ALISCA-Breast1 and ALISCA-Lung1, which appear to demonstrate an increased clinical effect of alisertib in biomarker subgroups where aurora kinase A appears to be playing a role. We look forward to continuing the development of alisertib in ALISCA-Breast1 and ALISCA-Lung1 while carefully managing our resources to achieve positive net income for this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBYI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBYI
Wall Street analysts forecast PBYI stock price to fall
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 8.220
Low
2.00
Averages
3.50
High
5.00
Current: 8.220
Low
2.00
Averages
3.50
High
5.00
No data
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nike Aims to Revitalize Business Through World Cup Engagement
- World Cup Opportunity: Nike sees the World Cup hosted in the U.S., Canada, and Mexico as a crucial opportunity for business recovery, particularly after over a year of restructuring, aiming to enhance brand visibility and market share.
- Innovative Product Launch: The introduction of Nike's new Aero-FIT technology significantly improves the breathability of soccer kits, expected to drive sales growth through World Cup exposure, with plans to expand this innovation across other sports.
- Community Engagement Activities: Nike has launched interactive retail and community experiences nationwide, such as the House of Merc in New York and Estadio Niky's in Los Angeles, aimed at attracting younger consumers and igniting their passion for soccer, thereby enhancing brand loyalty.
- Sales Growth Expectations: Analysts predict that the World Cup will yield substantial sales growth for Nike, particularly in the Asia-Pacific and Latin America regions, likely driving business recovery in the coming quarters, despite ongoing pressure on Nike's stock price.
See More
Abercrombie Expands Footwear Brands to Drive Growth
- Brand Expansion Strategy: Abercrombie's collaboration with brands like Puma and Sperry marks its first foray into external footwear, launching at a new 10,000-square-foot store in New York, aimed at attracting new customers and enhancing existing shoppers' spending, thereby strengthening market competitiveness.
- Customer Demand Response: The company noted frequent inquiries on social media about where to buy these shoes, indicating strong demand for external brands and highlighting the market's desire for product diversity, which could drive future sales growth.
- Sales Performance Challenges: Despite Abercrombie's impressive sales growth of over 98% from fiscal 2020 to 2024, the brand experienced a decline of over 1% in sales and a 7% drop in comparable sales during fiscal 2024 to 2025, reflecting intensified market competition and internal execution challenges.
- Competitive Environment Analysis: In response to strong performances from competitors like Aritzia, Abercrombie's expansion into external brands is seen as a crucial strategy for attracting potential customers, and while analysts believe the sales contribution from these brands may be limited, their potential for customer acquisition and brand exposure is significant.
See More
Puma Biotechnology Grants Stock Awards to New Employees
- Stock Award Program: On June 1, 2026, Puma Biotechnology approved the grant of 7,000 restricted stock units to two new non-executive employees, aimed at attracting talent and enhancing the company's appeal.
- Vesting Conditions: Under the 2017 Employment Inducement Incentive Award Plan, the stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued employee service.
- Product Development Progress: Puma focuses on developing innovative cancer treatment products, having received FDA approval for neratinib in 2017 for extended adjuvant treatment of early-stage HER2-positive breast cancer, marketed as NERLYNX®.
- Clinical Trial Initiation: In February 2024, Puma initiated the ALISCA™-Lung1 Phase II clinical trial for small cell lung cancer, marking significant progress in the development of the anti-cancer drug alisertib, which is expected to enhance the company's market position in cancer treatment.
See More
Puma Biotechnology Q1 2026 Earnings Call Highlights
- Revenue Performance: Puma reported total revenue of $44.8 million for Q1 2026, with product revenue at $42 million, impacted by an inventory drawdown of approximately $7.9 million, indicating shifts in sales dynamics through specialty pharmacies and distributors.
- Clinical Progress: In the ALISCA-Lung1 trial, Puma plans to increase alisertib dosage from 60 mg to 70 mg, with hopes to begin enrollment for the 70 mg cohort in the second half of 2026, demonstrating the company's ongoing commitment to R&D in small cell lung cancer.
- Outlook Adjustment: Puma raised its 2026 NERLYNX net product revenue guidance to a range of $202 million to $206 million, up from the previous $194 million to $198 million, reflecting increased confidence in future sales growth.
- Financial Status: The company reported a net loss of $3.8 million for Q1, translating to a loss of $0.07 per share; however, management anticipates full-year net income between $16 million and $19 million, indicating a trend towards improved profitability.
See More
Puma Biotechnology Grants Stock Awards to New Employees
- Stock Award Program: On May 5, 2026, Puma Biotechnology approved the grant of 59,750 restricted stock units to six new non-executive employees, aimed at attracting talent and enhancing the company's appeal.
- Vesting Conditions: Under the 2017 Employment Inducement Incentive Award Plan, the stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued employee service.
- Product Development Progress: Puma focuses on developing innovative cancer treatment products, with its NERLYNX® receiving FDA approval in 2017 for extended adjuvant treatment of early HER2-positive breast cancer, demonstrating the company's ongoing commitment in the oncology sector.
- Clinical Trial Initiation: In February 2024, Puma initiated the ALISCA™-Lung1 Phase II clinical trial for small cell lung cancer, marking a significant step in the development of the anti-cancer drug alisertib, which is expected to drive future market growth.
See More
Puma Biotechnology Grants Stock Awards to New Employees
- Stock Award Program: On April 1, 2026, Puma Biotechnology approved the grant of 31,625 restricted stock units to five new non-executive employees, aimed at attracting talent and enhancing the company's appeal.
- Vesting Conditions: Under the 2017 Employment Inducement Incentive Award Plan, the stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued employee service.
- Clinical Trial Progress: Puma is conducting two Phase II clinical trials, ALISCA™-Lung1 and ALISCA™-Breast1, targeting small cell lung cancer and HER2-negative, HR-positive metastatic breast cancer, demonstrating the company's ongoing commitment to cancer drug development.
- Market Authorization Status: Puma's NERLYNX® received FDA approval in 2017 for extended adjuvant treatment of early-stage HER2-positive breast cancer, further solidifying its market position in cancer care.
See More
Nike Aims to Revitalize Business Through World Cup Engagement
- World Cup Opportunity: Nike sees the World Cup hosted in the U.S., Canada, and Mexico as a crucial opportunity for business recovery, particularly after over a year of restructuring, aiming to enhance brand visibility and market share.
- Innovative Product Launch: The introduction of Nike's new Aero-FIT technology significantly improves the breathability of soccer kits, expected to drive sales growth through World Cup exposure, with plans to expand this innovation across other sports.
- Community Engagement Activities: Nike has launched interactive retail and community experiences nationwide, such as the House of Merc in New York and Estadio Niky's in Los Angeles, aimed at attracting younger consumers and igniting their passion for soccer, thereby enhancing brand loyalty.
- Sales Growth Expectations: Analysts predict that the World Cup will yield substantial sales growth for Nike, particularly in the Asia-Pacific and Latin America regions, likely driving business recovery in the coming quarters, despite ongoing pressure on Nike's stock price.
See More
Abercrombie Expands Footwear Brands to Drive Growth
- Brand Expansion Strategy: Abercrombie's collaboration with brands like Puma and Sperry marks its first foray into external footwear, launching at a new 10,000-square-foot store in New York, aimed at attracting new customers and enhancing existing shoppers' spending, thereby strengthening market competitiveness.
- Customer Demand Response: The company noted frequent inquiries on social media about where to buy these shoes, indicating strong demand for external brands and highlighting the market's desire for product diversity, which could drive future sales growth.
- Sales Performance Challenges: Despite Abercrombie's impressive sales growth of over 98% from fiscal 2020 to 2024, the brand experienced a decline of over 1% in sales and a 7% drop in comparable sales during fiscal 2024 to 2025, reflecting intensified market competition and internal execution challenges.
- Competitive Environment Analysis: In response to strong performances from competitors like Aritzia, Abercrombie's expansion into external brands is seen as a crucial strategy for attracting potential customers, and while analysts believe the sales contribution from these brands may be limited, their potential for customer acquisition and brand exposure is significant.
See More
Puma Biotechnology Grants Stock Awards to New Employees
- Stock Award Program: On June 1, 2026, Puma Biotechnology approved the grant of 7,000 restricted stock units to two new non-executive employees, aimed at attracting talent and enhancing the company's appeal.
- Vesting Conditions: Under the 2017 Employment Inducement Incentive Award Plan, the stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued employee service.
- Product Development Progress: Puma focuses on developing innovative cancer treatment products, having received FDA approval for neratinib in 2017 for extended adjuvant treatment of early-stage HER2-positive breast cancer, marketed as NERLYNX®.
- Clinical Trial Initiation: In February 2024, Puma initiated the ALISCA™-Lung1 Phase II clinical trial for small cell lung cancer, marking significant progress in the development of the anti-cancer drug alisertib, which is expected to enhance the company's market position in cancer treatment.
See More
Puma Biotechnology Q1 2026 Earnings Call Highlights
- Revenue Performance: Puma reported total revenue of $44.8 million for Q1 2026, with product revenue at $42 million, impacted by an inventory drawdown of approximately $7.9 million, indicating shifts in sales dynamics through specialty pharmacies and distributors.
- Clinical Progress: In the ALISCA-Lung1 trial, Puma plans to increase alisertib dosage from 60 mg to 70 mg, with hopes to begin enrollment for the 70 mg cohort in the second half of 2026, demonstrating the company's ongoing commitment to R&D in small cell lung cancer.
- Outlook Adjustment: Puma raised its 2026 NERLYNX net product revenue guidance to a range of $202 million to $206 million, up from the previous $194 million to $198 million, reflecting increased confidence in future sales growth.
- Financial Status: The company reported a net loss of $3.8 million for Q1, translating to a loss of $0.07 per share; however, management anticipates full-year net income between $16 million and $19 million, indicating a trend towards improved profitability.
See More
Puma Biotechnology Grants Stock Awards to New Employees
- Stock Award Program: On May 5, 2026, Puma Biotechnology approved the grant of 59,750 restricted stock units to six new non-executive employees, aimed at attracting talent and enhancing the company's appeal.
- Vesting Conditions: Under the 2017 Employment Inducement Incentive Award Plan, the stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued employee service.
- Product Development Progress: Puma focuses on developing innovative cancer treatment products, with its NERLYNX® receiving FDA approval in 2017 for extended adjuvant treatment of early HER2-positive breast cancer, demonstrating the company's ongoing commitment in the oncology sector.
- Clinical Trial Initiation: In February 2024, Puma initiated the ALISCA™-Lung1 Phase II clinical trial for small cell lung cancer, marking a significant step in the development of the anti-cancer drug alisertib, which is expected to drive future market growth.
See More
Puma Biotechnology Grants Stock Awards to New Employees
- Stock Award Program: On April 1, 2026, Puma Biotechnology approved the grant of 31,625 restricted stock units to five new non-executive employees, aimed at attracting talent and enhancing the company's appeal.
- Vesting Conditions: Under the 2017 Employment Inducement Incentive Award Plan, the stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued employee service.
- Clinical Trial Progress: Puma is conducting two Phase II clinical trials, ALISCA™-Lung1 and ALISCA™-Breast1, targeting small cell lung cancer and HER2-negative, HR-positive metastatic breast cancer, demonstrating the company's ongoing commitment to cancer drug development.
- Market Authorization Status: Puma's NERLYNX® received FDA approval in 2017 for extended adjuvant treatment of early-stage HER2-positive breast cancer, further solidifying its market position in cancer care.
See More
